Vous êtes sur la page 1sur 2

Federal Register / Vol. 71, No.

89 / Tuesday, May 9, 2006 / Notices 26977

request IHS Tribal Management Grant ADDRESSES: Licensing information and disorders. Other diseases that can be
room block. Hotel rate: $66.00 plus tax. copies of the U.S. patent applications diagnosed include diabetes, cystic
• May 22–26, 2006—Rapid City, listed below may be obtained by writing fibrosis, homocystenuria, Hermansky-
South Dakota (Limit 25). Training to the indicated licensing contact at the Pudlak syndrome, cystinosis, Zellweger
Registration and Hotel Reservation Office of Technology Transfer, National syndrome, beta-thalassemia,
deadline: May 1, 2006. Ramada Inn Institutes of Health, 6011 Executive alkaptonuria, and cancer.
Rapid City, 1721 Lacrosse Street, Rapid Boulevard, Suite 325, Rockville, A variety of diseases appear to be
City, SD 57701. 1–866–742–1300 or Maryland 20852–3804; telephone: (301) mediated or accompanied by aberrant
605–342–1300; please request IHS 496–7057; fax: (301) 402–0220. A signed expression of one allele, often a mutant
Tribal Management Grant room block. Confidential Disclosure Agreement will of a gene. Such differences in allelic
Hotel rate: $59.00 plus tax. be required to receive copies of the expression can serve as the basis for
• June 14–15, 2006—Oklahoma City, patent applications. diagnostic test for such conditions, and
Oklahoma (Limit 25). Training New Method for Quantification of the ability to specifically silence the
Registration and Hotel Reservation Allele-Specific RNA Expression, That expression of detrimental alleles could
deadline: May 30, 2006. Best Western Can Be Used for Detection of Various be a therapeutic method for treating the
Saddleback Inn, 4300 Southwest Third Genetic Disorders disease, hence this novel method has
Street, Oklahoma City, OK 73108. 1– very wide applications.
Drs. Marjan Huizing, Enriko Klootwijk,
800–228–3903 or 405–947–7000, Development of Gene Chip Technology
Paul Savelkoul, Carla Ciccone,
extension 3123; please request IHS for Vascular Risk Assessment
William Gahl (NHGRI)
Tribal Management Grant room block. U.S. Provisional Application No. 60/
Hotel rate: $67.00 plus tax. Alison E. Baird (NINDS) et al.
718,321 filed 20 Sep 2005 (HHS U.S. Provisional Application No. 60/
The Public Health Service (PHS) Reference No. E–146–2005/0–US–01)
strongly encourages all grant and 687,515 filed 03 Jun 2005 (HHS
Licensing Contact: Cristina
contract recipients to provide a smoke- Reference No. E–030–2005/0–US–01)
Thalhammer-Reyero; 301/435–4507;
free workplace and promote the non-use U.S. Provisional Application No. 60/
of all tobacco products. In addition, 691,730 filed 17 Jun 2005 (HHS
Available for licensing and Reference No. E–030–2005/1–US–01)
Public Law 103–227, the Pro-Children commercial development is a new
Act of 1994, prohibits smoking in Licensing Contact: Fatima Sayyid; 301/
method for quantification of allele- 435–4521; sayyidf@mail.nih.gov.
certain facilities (or in some cases, any specific RNA expression. This invention
portion of the facility) in which regular describes methods for simultaneously Prevention of cardiovascular
or routine education, library, day care, detecting the levels of expression of a disorders such as myocardial infarction
health care or early childhood plurality of different RNA transcripts and stroke is an area of major public
development services are provided to expressed from a gene of interest in a health importance. Currently, several
children. This is consistent with the subject or a cell. This is a simple assay risk factors for future cardiovascular
HHS mission to protect and advance the to validate and quantify allele-specific disorders have been described and are
physical and mental health of the silencing, by applying a combination of in wide clinical use in the detection of
American people. a fluorescent primer/probe set that individuals at high risk. However a large
Dated: May 2, 2006. specifically recognizes the targeted number of cardiovascular disorders
allele where the probe is labeled with occur in individuals with apparently
Robert G. McSwain,
one fluorophore, and a primer/probe set low to moderate risk profiles, thereby
Deputy Director, Indian Health Service.
that specifically recognizes the normal limiting the ability to identify such
[FR Doc. 06–4292 Filed 5–8–06; 8:45 am] patients. Moreover, many of the risk
allele, where the probe is labeled with
another fluorophore in the same factors require accurate gathering of
reaction tube. Furthermore, this method clinical information. An objective panel
can be run on most real time PCR of biological markers which allow one
DEPARTMENT OF HEALTH AND to predict an individual’s risk of
HUMAN SERVICES machines and requires very small
amounts of RNA, less than 100 ng. This vascular disease is therefore needed.
National Institutes of Health novel method, by comparing alleles The present provisional patent
within the same gene, expands on application is directed to utilizing blood
Government-Owned Inventions; current real time PCR methods which mononuclear cells to evaluate vascular
Availability for Licensing compare one gene with another gene. disease risk and determine a preventive
The invention also describes methods regimen for reduction or minimization
AGENCY: National Institutes of Health, for validating the effectiveness and of such risk. The method includes
Public Health Service, HHS. specificity of allele-specific siRNAs, kits screening for differential expression of
ACTION: Notice. for performing such assays, as well as vascular risk-related molecules, such as
methods for diagnosis of autosomal- DNA binding/transcription factor
SUMMARY: The inventions listed below dominant disorders, in which mutations proteins, lysosomal or protein
are owned by an agency of the U.S. in one allele result in a disease degradation enzymes, adhesion
Government and are available for phenotype, such as Hutchinson-Gilford molecules, metabolism molecules,
licensing in the U.S. in accordance with progeria, incontinentia pigmenti, intracellular signaling molecules,
35 U.S.C. 207 to achieve expeditious neurofibromatosis, myotonic dystrophy, immune response molecules and
commercialization of results of sialuria, Machado-Joseph disease, apoptosis. The technology is available to
mstockstill on PROD1PC68 with NOTICES

Federally-funded research and spinocerebellar ataxia, frontotemporal a collaborator for monitoring stroke
development. Foreign patent dementia, amyotrophic lateral sclerosis, treatment protocols, for definition of
applications are filed on selected slow channel congenital myasthenic clinical trial protocol candidates, or for
inventions to extend market coverage syndrome, spinobulbar muscular developing an ‘‘assessment chip’’ that
for companies and may also be available dystrophy, as well as compound could be used to predict an individual’s
for licensing. heterozygous autosomal recessive risk of developing a stroke in the future.

VerDate Aug<31>2005 15:42 May 08, 2006 Jkt 208001 PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\09MYN1.SGM 09MYN1
26978 Federal Register / Vol. 71, No. 89 / Tuesday, May 9, 2006 / Notices

The NINDS Stroke Neuroscience Unit include removal of the kidney would constitute a clearly unwarranted
is seeking statements of capability or (nephrectomy) or high dose invasion of personal privacy.
interest from parties interested in immunotherapy with IL-2, which has Name of Committee: National Institute of
collaborative research to further been able to achieve success in only part Child Health and Human Development
develop, evaluate, or commercialize a (15–20%) of the patient population. Special Emphasis Panel, Data Coordinating
vascular risk genetic chip technology. Even with a successful nephrectomy, it Center for Consortium on Safe Labor.
We seek a collaborative partner in the is likely that patients with advanced Date: May 22, 2006.
development of a chip that could be local diseases will develop metastases. Time: 8 a.m. to 5 p.m.
used to predict an individual’s risk of Therefore, new methods are needed to Agenda: To review and evaluate contact
developing a stroke in the future and to improve on IL-2 therapy and expand the Place: Ramada Inn Rockville, 1775
monitor the effectiveness of preventive curative potential of therapies for Rockville Pike, Rockville, MD 20852.
measures once they have been patients with RCC. Contact Person: Hameed Khan, PhD,
instituted. Please contact Heather Gunas The present invention discloses Scientific Review Administrator, Division of
at gunash@mail.nih.gov for more peptides for use in immunotherapy of Scientific Review, National Institute of Child
information. tumors. The peptides, both an HLA-A2 Health and Human Development, NIH, 6100
and an HLA-A3 epitope, are derived Executive Blvd., Room 5B01, Bethesda, MD
Method of Inducing Memory B Cell 20892, (301) 435–6902, khanh@mail.nih.gov.
Development and Terminal from the amino acid sequence of an
RCC-associated antigen, fibroblast Name of Committee: National Institute of
Differentiation Child Health and Human Development
growth factor-5 (FGF–5). Plans are Special Emphasis Panel, Consumers’ Report
Peter E. Lipsky (NIAMS) et al. underway to investigate both peptides
U.S. Patent Application No. 11/197,221 on Prosthetics and Assistive Technology.
in clinical trials of peptide vaccination Date: May 25, 2006.
filed 03 Aug 2005 (HHS Reference No. in patients with advanced renal cancer. Time: 12 p.m. to 2 p.m.
E–120–2003/2–US–01) In addition, FGF–5 also appears to be Agenda: To review and evaluate contract
Licensing Contact: Thomas Clouse; 301/ over-expressed in other common proposals.
435–4076; clousetp@mail.nih.gov. adenocarcinomas such as breast, Place: National Institutes of Health, 6100
Cytokines exert their respective prostate and bladder cancer and very Executive Boulevard, Room 5B01, Rockville,
biochemical and physiological effects by few antigens suitable for vaccine MD 20852, (Telephone Conference Call).
binding to specific receptor molecules, Contact Person: Hameed Khan, PhD,
therapies exist for those cancers. Scientific Review Administrator, Division of
which then stimulate signal In addition to licensing, the Scientific Review, National Institute of Child
transduction pathways. Interleukin-21 technology is available for further Health and Human Development, NIH, 6100
(1L-21) is a type I cytokine whose development through collaborative Executive Blvd., Room 5B01, Bethesda, MD
receptor is expressed on T, B, and NK research opportunities with the 20892, (301) 435–6902, khanh@mail.nih.gov.
cells. inventors. (Catalogue of Federal Domestic Assistance
This invention specifically relates to Program Nos. 93.864, Population Research;
Dated: May 2, 2005.
the use of IL-21 to induce differentiation 93.865, Research for Mothers and Children;
of immature B cells into memory B cells David R. Sadowski, 93.929, Center for Medical Rehabilitation
and plasma cells. This invention Acting Director, Division of Technology Research; 93.209, Contraception and
includes claims of methods for inducing Development and Transfer, Office of Infertility Loan Repayment Program, National
Technology Transfer, National Institutes of Institutes of Health, HHS)
differentiation of a B cell progenitor into
memory B cells and/or plasma cells. It Dated: April 30, 2006.
[FR Doc. E6–6987 Filed 5–8–06; 8:45 am]
also includes claims for enhancing an Anna Snouffer,
immune response, treating subjects that Acting Director, Office of the Federal Advisory
lack memory B cells and plasma cells Committee Policy.
and methods for increasing or [FR Doc. 06–4297 Filed 5–8–06; 8:45am]
decreasing the number of B cells. This BILLING CODE 4140–01–M
invention could conceivably be used in
treating or preventing inflammatory National Institutes of Health
disorders, autoimmune diseases, DEPARTMENT OF HEALTH AND
allergies, transplant rejection, cancer, National Institute of Child Health and HUMAN SERVICES
and other immune system disorders. Human Development; Notice of Closed
Meetings National Institutes of Health
Immunogenic Epitopes for Fibroblast
Growth Factor-5 (FGF–5) Presented by Pursuant to section 10(d) of the National Institute of Diabetes and
HLA-A3 and HLA-A2 Federal Advisory Committee Act, as Digestive and Kidney Diseases; Notice
James C. Yang et al. (NCI) amended (5 U.S.C. Appendix 2), notice of Closed Meeting
U.S. Patent Application No. 11/134,703 is hereby given of the following Pursuant to section 10(d) of the
filed 19 May 2005 (HHS Reference meetings. Federal Advisory Committee Act, as
No. E–031–2003/1–US–01) The meetings will be closed to the amended (5 U.S.C. Appendix 2), notice
Licensing Contact: Michelle Booden; public in accordance with the is hereby given for the following
301/451–7337; provisions set forth in sections meeting.
boodenm@mail.nih.gov. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., The meeting will be closed to the
Approximately 30,000 patients are as amended. The contract proposals and public in accordance with the
mstockstill on PROD1PC68 with NOTICES

diagnosed with renal cell carcinoma the discussions could disclose provisions set forth in sections
(RCC) each year in the United States, confidential trade secrets or commercial 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
and an estimated 12,000 patients die of property such as patentable material, as amended. The grant applications and
this disease. Most patients are and personal information concerning the discussions could disclose
diagnosed with advanced local disease individuals associated with the contract confidential trade secrets or commercial
or metastatic disease. Current therapies proposals, the disclosure of which property such as patentable material,

VerDate Aug<31>2005 15:42 May 08, 2006 Jkt 208001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 E:\FR\FM\09MYN1.SGM 09MYN1